1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1510
https://www.valueinhealthjournal.com/article/S1098-3015(18)31816-3/fulltext
Title :
1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31816-3&doi=10.1016/j.jval.2018.04.1510
First page :
Section Title :
Open access? :
No
Section Order :
749